

The Readout Loud
STAT
STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.
Episodes
Mentioned books

Dec 14, 2023 • 35min
286: FTC v. biotech, Pfizer's kitchen sink, & Vertex's future
FTC blocks Sanofi-Maze Therapeutics deal, Pfizer's downbeat future, Vertex's next big thing, and Reed Jobs' journey into biotech venture capital.

Dec 7, 2023 • 37min
285: CRISPR history, biotech struggles, & a big week for deals
Megan Molteni discusses the history and future of CRISPR-based medicine and the expected FDA approval of the first CRISPR-based medicine. Bruce Booth joins to discuss the challenges faced by the biotech industry and prospects for optimism in 2024.

Nov 30, 2023 • 29min
284: AbbVie’s big deal, CAR-T’s risks, & getting a biotech job
AbbVie, a company spending $10 billion on a cancer-focused company on its first FDA approval. Implications for biotech in 2023 and oncology. Safety concerns for CAR-T cancer treatment. Slumping industry job market. Curious explanations for clinical failures.

11 snips
Nov 16, 2023 • 31min
283: A CRISPR milestone, algorithms amok, & biotech mixology
Investigative reporter Casey Ross reveals how UnitedHealth Group used an algorithm to deny patient care for profit. Biotech veteran Michael Gilman talks about being a startup CEO in the economic downturn and shares cocktail recipes. They also discuss the approval of a groundbreaking CRISPR-based medicine.

Nov 13, 2023 • 30min
From Tradeoffs: Can the U.S. put an end to surprise ambulance bills?
This podcast discusses the ongoing problem of surprise ambulance bills in the US. It highlights the financial burden on patients and the difficulty in finding a fair solution. Personal stories are shared to emphasize the high costs and frustration faced by patients. Different approaches taken by states and the need for a public reckoning in emergency services are explored. The potential consequences of congressional inaction are also discussed, but there is a glimmer of hope with one person receiving a zero-dollar bill due to an insurance error.

Nov 9, 2023 • 37min
282: Lilly’s obesity drug, the power of radiation, & a biotech implosion
This podcast explores the scientific backstory of radiopharmaceuticals, Eli Lilly's new obesity drug, a biotech implosion, and shareholder activism. They also discuss the approval and pricing of Lilly's weight loss drug, upcoming cardiovascular outcome study for Novo Nordisk's WeGoV, and updates in the pharmaceutical industry. Additionally, they delve into the history of the radiopharmaceutical Zevelin and a bittersweet day for IDEC and Zevelin employees during an FDA advisory panel meeting.

11 snips
Nov 2, 2023 • 32min
281: Decoding biotech hype, the Sarepta saga, & au revoir to a CEO
Biotech consultant Frank David explains subgroup analyses and how they can be misleading. The podcast also discusses the future of Sarepta and the retirement of a biotech stalwart.

Oct 26, 2023 • 30min
280: ESMO highlights, Roivant's big deal, & biotech VC on the rise
The podcast discusses the highlights of a recent oncology conference, including advancements in cancer-treating technology. It also covers the future of Alzheimer's disease treatment, a multibillion-dollar biotech deal, and the rise of biotech venture capital. The hosts explore the incredible math behind a biotech investment that turned $50 million into $5 billion. They also discuss the challenges faced by the biotech industry, recent developments in Alzheimer's treatment, and advancements in antibody-drug conjugates for cancer treatment.

Oct 19, 2023 • 33min
279: Live from the 2023 STAT Summit
Live from the 2023 STAT Summit, the hosts discuss genome editing milestones, twists in ALS treatments, and the polarizing process of pronouncing words in biotech. They also explore the potential impact of in vivo gene editing therapy, debates over pronunciation of acronyms and drug names, and the future of neurodegenerative diseases research.

Oct 12, 2023 • 33min
278: Merger Mondays, Ozempic panic, & CRISPR'd pigs
The podcast discusses Bristol Myers Squibb's acquisition of Mirati Therapeutics, the rejection of a treatment by Al Nylon, the impact of GLP-1 drugs on the Nash treatment market, and advancements in genetic engineering using CRISPR technology in animals.